Researcher Profile

Researcher Profile

David Waning, PhD

David Waning, PhD

Associate Professor, Department of Cellular and Molecular Physiology
Scientific Program:Experimental Therapeutics
dlw83@psu.edu
View Website

Research Interests

Dr. David Waning's research focuses on the emerging importance of bone-muscle crosstalk in aging and disease.

The overarching goal of his research program is to discover and characterize molecular mechanisms that impair musculoskeletal health in disease and aging. Bone and muscle are tightly coupled during growth and development, and also during aging and disease yet the cellular and molecular mechanisms linking these two tissues are not well understood. The Waning lab is developing novel therapeutic approaches that improve musculoskeletal health in pre-clinical models of cancer and chemotherapy-induced sequelae, osteoporosis and aging.

The major aims of Dr. Waning's research are to identify and characterize signal mediators of bone-muscle crosstalk that affect musculoskeletal health. He is especially interested in identifying targets of oxidative stress that affect bone and muscle function; understanding muscle weakness in cachexia; cachexia and the relative contribution of muscle wasting and contractile dysfunction; and bone-muscle crosstalk in rare bone diseases.

  • Bone and Bones
  • Neoplasms
  • Muscles
  • Neoplasm Metastasis
  • Muscle Weakness
  • Proteins
  • Therapeutics
  • Bone Neoplasms
  • Skeletal Muscle
  • Breast Neoplasms
  • DNA Damage
  • Osteoblasts

Recent Publications

2019

Waning, D, Guise, TA & Mohammad, KS 2019, 'A “Connexin” Responsible for the Fatal Attraction of Cancer to Bone' Cell Metabolism, vol. 29, no. 1, pp. 6-8. https://doi.org/10.1016/j.cmet.2018.12.014
[C@61b90911

2017

[C@4f2f2a25
[C@7c62fc52
[C@1f5255b1
[C@5e5099b8
[C@51cdf0e9

2016

[C@69def449
[C@1d49643c

2015

[C@49d65c3d
Cheng, YH, Streicher, DA, Waning, D, Chitteti, BR, Gerard-O'Riley, R, Horowitz, MC, Bidwell, JP, Pavalko, FM, Srour, EF, Mayo, LD & Kacena, MA 2015, 'Signaling pathways involved in megakaryocyte-mediated proliferation of osteoblast lineage cells', Journal of Cellular Physiology, vol. 230, no. 3, pp. 578-586. https://doi.org/10.1002/jcp.24774

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)